Zhimeng Biopharma Overview

  • Founded
  • 2017

Founded
  • Status
  • Private

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $54.6M

  • Investors
  • 16

Zhimeng Biopharma General Information

Description

Developer of pharmaceuticals designed to target all stages of the hepatitis B virus. The company has nuclecapsid inhibitor, RNA destabilizer and immunomodulator projects in the pipeline, enabling healthcare professionals to prescribe better treatments to patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Suite A-302
  • No. 1976 Gaoke Middle Road, China (Shanghai) Pilot Free Trade Zone
  • Shanghai, 201210
  • China
+86 021 0000 0000

Zhimeng Biopharma Timeline

2019202020212022
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zhimeng Biopharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 08-Nov-2021 $54.6M 00000 00000 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series A) 06-Nov-2020 000.00 000.00 Completed Clinical Trials - Phase 1
2. Early Stage VC 11-Nov-2019 $14.2M $14.2M Completed Clinical Trials - Phase 1
1. Early Stage VC 05-Feb-2018 Completed Startup
To view Zhimeng Biopharma’s complete valuation and funding history, request access »

Zhimeng Biopharma Patents

Zhimeng Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020333708-A1 2-aminopyrimidine compounds and pharmaceutical compositions and uses thereof Pending 19-Aug-2019 00000000
CA-3147836-A1 2-aminopyrimidine compounds and pharmaceutical compositions and uses thereof Pending 19-Aug-2019 00000000
EP-4019517-A1 2-aminopyrimidine compounds and pharmaceutical compositions and uses thereof Pending 19-Aug-2019 0000000000
AU-2019272383-A1 P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof Granted 22-May-2018 0000000000
CA-3101226-A1 P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof Pending 22-May-2018 C07D451/00
To view Zhimeng Biopharma’s complete patent history, request access »

Zhimeng Biopharma Executive Team (3)

Name Title Board Seat Contact Info
Huanming Chen Ph.D Chief Executive Officer, President & Co-Founder
Zhijun Zhang Co- Founder, Chief Scientific Officer & Vice President
Ming Ren Ph.D Chief Medical Officer
To view Zhimeng Biopharma’s complete executive team members history, request access »

Zhimeng Biopharma Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Advantech Capital Partners Growth/Expansion Minority 000 0000 000000 0
Co-Stone Capital PE/Buyout Minority 000 0000 000000 0
Dawu Venture Capital Venture Capital Minority 000 0000 000000 0
DYEE Capital Venture Capital Minority 000 0000 000000 0
Fellow Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »